All News

"Cretostimogene is a novel therapy which has the potential to be a paradigm shift in how we might manage the ongoing burden of this highly recurrent aspect of bladder cancer,” says Neal D. Shore, MD, FACS.

The Decipher test is a 22-gene prognostic tool used for the risk stratification of patients with localized prostate cancer.

Adjuvant chemotherapy after nephroureterectomy continued to show an efficacy benefit versus surveillance in patients with upper tract urothelial cancer, according to long-term follow-up data from the phase 3 randomized POUT trial.

“These clinical data show encouraging safety and efficacy with JANX007 in metastatic castration-resistant prostate cancer and with JANX008 in late-stage solid tumors," says David Campbell, PhD.

Interim data from the study showed that at 6 months following implantation, 80% (4 of 5) of evaluable women with mixed UI experienced a complete resolution of incontinence episodes.

The FDA approval is supported by data from the phase 3 ALLIUM trial, which demonstrated the non-inferiority and superiority of cefepime/enmetazobactam vs piperacillin/tazobactam.

Postoperative urinary retention is a common outcome after surgical procedures for pelvic organ prolapse and stress urinary incontinence.

Clara Hwang, MD, is the lead author of the study, “Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer.”

In total, the investigators assessed data from 886 patients with advanced kidney cancer who were randomly assigned to receive avelumab plus axitinib or subitinib.

The CELC-G-201 trial is assessing the safety, preliminary efficacy, and pharmacokinetics of gedatolisib plus darolutamide in mCRPC

Daniel Spratt, MD, highlights the evolving paradigm of PET-based imaging agents in prostate cancer, with a focus on the impact of PSMA-PET imaging.

The FDA has issued a complete response letter regarding a new drug application for cefepime-taniborbactam for the treatment of patients with complicated urinary tract infection.

In total, the phase 1/2 PRESERVE-006 trial is expected to enroll 144 patients across 20 clinical trial sites in the US.

"We have over 30 years of safety data, and no adverse events in over 30 years," says Heather Florio.

For 90-tablet prescriptions, the greatest costs saving were observed for solifenacin and oxybutynin, used for overactive bladder, and tadalafil, used for erectile dysfunction

The position statement is meant to iterate AUGS' support for gender inclusion of both patients and health care providers.

Those who experienced a response with neoadjuvant chemotherapy had a median overall survival of 73.0 months, compared with 17.0 months among non-responders.

Overall, the patient met the study’s primary outcome measures of successful device activation and the rate of explants and revisions at 6 months.

All patients treated with 177Lu-rhPSMA-10.1 had reductions in their PSA levels from the start of treatment and none experienced a serious treatment-related adverse event.

Cefepime-taniborbactam is currently under review by the FDA for cUTI, including acute pyelonephritis, based on data from the CERTAIN-1 trial.

The purpose of this clinical consensus statement is to identify areas of expert consensus and nonconsensus regarding pessary fitting, follow-up, and management of pessary complications to improve the safety and quality of care where evidence is currently limited.

"Post-hoc sensitivity analyses from the phase 3 ARASENS trial presented at ASCO GU were consistent with and supportive of the ARASENS primary OS analysis–reinforcing darolutamide plus ADT plus docetaxel as an effective and well tolerated standard of care in patients with mHSPC," writes Neal Shore, MD, FACS.

"Urologists may wish to review their policies for patient portal, responding to requests for records, and supporting the concept of a shared electronic record," writes Robert A. Dowling, MD.

Researchers sought to understand if a lack of cancer progression as monitored by radiography could substitute overall survival as a metric for metastatic prostate cancer clinical trials.

The sNDA, which was submitted in January 2024, is supported by findings from the phase 3 EV-302 trial.

The funds will support ZERO Prostate Cancer’s Black Men’s Prostate Cancer Initiative, which provides aid to Black and Brown communities who are at higher risk of prostate cancer.

Over 60% of the analyzed abstracts contained language that did not follow the ASCO Language of Respect guidelines.

In patients where SOC imaging was unable to detect any lesions, 64Cu-SAR-bisPSMA was able to identify lesions in approximately 60% of patients on same-day imaging and up to 80% on next-day imaging.